Pfizer has developed a vaccine specifically for Omicron

Pfizer and BioNTech have announced that they have developed a new vaccine specifically for the COVID-19 Omicron variant.

They are launching clinical trials to prove its safety and effectiveness, as well as what immune response the drug elicits, both as an initial vaccine and as a booster dose.

Also read: Omicron does not confer immunity and does not protect unvaccinated people from other strains of COVID-19

The vaccine will be tested among 1,420 healthy adults between the ages of 18 and 55, two companies added, CNN reported.

The study was divided into three groups: participants in the first cohort received two doses of the current Pfizer vaccine at least 90-180 days before the study. They will also receive one or two doses of a specific vaccine against Omicron.

Participants in the second group received three doses of the current Pfizer vaccine at least 90-180 days before the study. They will receive one dose of the new drug Omicron.

Participants in the third group did not receive the COVID-19 vaccine. They will receive three doses of the specific vaccine Omicron.

The new vaccine will be given at a dose of 30 mcg, which corresponds to the current vaccine against COVID-19.

Wait for the details.

Earlier, the DIP reported that “Blue nails, lips or skin – one of the new symptoms of Omicron.”